Re Review on Antimicrobial Resistance

RNS Number : 2924D

Redx Pharma plc

23 October 2015

 

23 October 2015

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company" or "the Group")

Redx Pharma welcomes latest paper from Review on Antimicrobial Resistance

Redx Pharma, the drug discovery and development company, welcomes the publication today of a fourth paper prepared by The Review on Antimicrobial Resistance, chaired by Jim O'Neill. The paper focuses on the use of rapid diagnostics in tackling the problem of unnecessary use of antibiotics and in improving the treatment of infections.

The report notes that the world needs a step change in the way that technology is incorporated into the decision-making process around antibiotic use - whether that be in the home, the pharmacy, a doctor's surgery or hospital.

It states that more refined tests, able to identify the strain of bacterial infection and the antibiotics to which it is resistant or susceptible, will allow more precise prescribing of narrow spectrum antibiotics. This in turn reduces our dependence on broad-spectrum products, slowing the development of resistance and improving the treatment that patients receive.

The report, entitled Rapid Diagnostics: Stopping Unnecessary Use of Antibiotics can be found on the following link http://amr-review.org/sites/default/files/Paper-Rapid-Diagnostics-Stopping-Unnecessary-Prescription.pdf

Dr Neil Murray, chief executive of Redx Pharma, commented:

"We welcome this latest report from the Review that highlights the critical issue of AMR. As the report states, rapid diagnostics can play a vital role in both limiting the unnecessary use of antibiotics and in promoting more precise prescription of narrow spectrum antibiotics. Alongside this, there is an urgent need for new drugs, as resistance grows, which Redx is looking to develop."

For further information, please contact:

Redx Pharma Plc		T: 0151 706 4747
Neil Murray, Chief Executive Company website: redxpharma.com
KTZ Communications		T: 020 3178 6378
Katie Tzouliadis

About Redx Pharma Plc

www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 13 proprietary (patent‑protected) drug programs. Five programs have now achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

About the Review on Antimicrobial Resistance

The UK Prime Minister commissioned the Review on Antimicrobial Resistance to address the growing global problem of drug-resistant infections. It is chaired by Jim O'Neill and supported by the Wellcome Trust and UK Government, but operates and speaks with full independence from both.

 

END

 

 

NRAPKNDPNBDDAKB